Premium
Neuroleptic dose and schizophrenic symptoms
Author(s) -
Peralta V.,
Cuesta M. J.,
Caro F.,
MartinezLarrea A.
Publication year - 1994
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1111/j.1600-0447.1994.tb01606.x
Subject(s) - haloperidol , hostility , chlorpromazine , schizophrenia (object oriented programming) , medicine , positive and negative syndrome scale , psychiatry , psychology , psychosis , clinical psychology , dopamine
A study was conducted to survey the prescribing practices of neuroleptic doses in 100 consecutively hospitalized DSM‐III‐R schizophrenic patients. The relationship between doses and clinical and symptomatological variables was subsequently analyzed. Patients were evaluated through the Positive and Negative Syndrome Scale (PANSS). The peak mean dose in chlorpromazine equivalents was 1290 (range 250–7200). Haloperidol was the most commonly employed neuroleptic (67 patients). Neuroleptic doses were correlated with excitement, suspiciousness, hostility, uncooperativeness and poor impulse control. The neuroleptic doses administered in our hospital were similar to those found in other survey reports but higher than those recommended by the controlled dose‐response studies. The correlation found between neuroleptic doses and symptoms of disruptive behavior suggests that we employed high‐dose practices to treat the disruptive symptoms of schizophrenia. We concluded that it is useful to distinguish between the neuroleptic doses required to control the psychotic episode and those to treat the disruptive behavior.